Indeed, the application of complex algorithms (e.g. maternal historical and demographic risk factors, blood pressure, uterine artery pulsatility index on Doppler velocimetry, and maternal serum biomarkers such as pregnancy-associated plasma protein A [PAPP-A] and PlGF) to identify women at risk for preeclampsia and use of LDA might also lead to a reduction of PE development52. The gene discussed is PAPPA; the disease is preeclampsia.